The real investment opportunity in brain-computer interfaces (BCIs) may not be the headline companies like Neuralink, but rather the lesser-known suppliers that every BCI startup depends on. A veteran trader has identified a basket of 14 publicly traded companies that provide the critical technologies needed to map and emulate brains, from ultrasound chips to protein sequencers to high-bandwidth memory systems. These suppliers are trading at valuations that don't reflect the potential impact of the underlying brain-mapping thesis.

Why Are Brain-Mapping Milestones Accelerating?

The scientific foundation for this investment thesis rests on a remarkable achievement: researchers have already completed a full digital map of a microscopic roundworm called C. elegans, documenting every neuron and every connection. Last year, scientists mapped a marine worm with three times as many neurons. These milestones raise an urgent question: if we can map a worm's brain, how long until we map a mouse's brain, and eventually a human brain ?

The answer depends on scaling the technologies that make connectomics research possible. That's where the supply chain comes in. Companies that manufacture electron microscopes, sequencing equipment, specialized memory systems, and computing platforms are the unglamorous but essential infrastructure for the brain-mapping revolution.

How Does the "Picks and Shovels" Strategy Apply to Brain-Computer Interfaces?

Market history shows a consistent pattern: when transformative technologies emerge, the largest investment returns rarely come from the consumer-facing brands. Instead, they flow to the suppliers. During the California Gold Rush, prospectors made modest returns, but Levi Strauss, which supplied miners with durable goods, became extraordinarily wealthy. The dot-com era is remembered for failed companies like Pets.com and Webvan, but Cisco, Oracle, and Sun Microsystems, which provided the underlying infrastructure, survived and compounded wealth for decades. The smartphone revolution is associated with Apple, but Taiwan Semiconductor and ASML, which manufacture the components Apple depends on, have produced extraordinary returns.

The brain-computer-interface revolution will follow the same pattern. Neuralink and Merge Labs will capture headlines and investor attention. But the supply chain companies that provide the essential technologies will likely deliver the most significant returns.

What Are the Key Supply Chain Categories?

• Ultrasound-Based BCI Technology: Butterfly makes a handheld, chip-based ultrasound device. In the fourth quarter of 2025, the company reported revenue of $31.5 million, up 41 percent year-over-year, and achieved its first quarter of positive operating cash flow in company history. Full-year 2026 revenue guidance is $117 million to $121 million, implying 20 to 24 percent growth. Butterfly's ultrasound-on-chip technology is licensed into Forest Neurotech, a brain-computer interface research organization that is part of the Convergent Research and Schmidt Futures Network. Both Forest and Merge Labs, Sam Altman's BCI startup, are pursuing ultrasound-based brain interfaces rather than electrode-based ones.
• Protein Sequencing: Quantum-Si is the only commercial single-molecule protein sequencer on the market. Connectomics research consistently identifies protein sequencing as a critical technology for any serious effort to digitally map a brain. However, revenue is only $2.4 million, making this a pre-commercial play with significant upside potential but also meaningful downside risk.
• Portable Brain Imaging: Hyperfine makes the only FDA-cleared portable brain MRI in the world. Their Swoop system brings brain scanning to the bedside, and recent international approvals are opening markets worth several hundred million dollars annually.
• Computing Infrastructure: NVIDIA's Holoscan platform powers Synchron's brain-interface decoder. Whichever consumer brain-interface technology wins, NVIDIA is likely to be the compute platform underneath. Micron Technology addresses the memory-bandwidth bottleneck that has become the real constraint for both artificial intelligence workloads and brain emulation.
• Medical Device Distribution: Medtronic has announced a distribution partnership with Precision Neuroscience, giving the company exposure to the BCI market without having to build the technology themselves.

What Strategic Signals Are Emerging From Major AI Companies?

In January 2026, OpenAI led a $252 million funding round into Merge Labs, a brain-computer interface startup co-founded by Sam Altman, valuing the company at $850 million. The structure raised eyebrows in the financial press given the circular dynamic of OpenAI investing in a company Altman co-founded. However, the substantive signal is significant: one of the most strategically positioned investors in artificial intelligence has decided brain-computer interfaces are worth a nine-figure investment.

This move suggests that major AI companies view BCIs not as a distant speculative technology, but as a near-term strategic priority. When OpenAI commits that level of capital to a BCI startup, it signals confidence that the underlying science is advancing faster than the public realizes.

Why Does the Memory Bottleneck Matter for Brain Emulation?

Over the last 30 years, computing power has roughly doubled every two years, following Moore's Law. However, memory bandwidth has grown only about 1.6 times in the same period. That gap is the real bottleneck for both artificial intelligence workloads and brain emulation. As researchers attempt to digitally map and simulate increasingly complex brains, they will hit memory constraints long before they hit processing power constraints. Micron Technology is positioned as the cleanest U.S.-listed pure-play on high-bandwidth memory, though the stock is cyclical and timing matters.

What Should Investors Know About Valuation Risk?

When Neuralink and Merge Labs eventually go public, retail investors will likely pile into these headline names. However, the valuations on those initial public offerings will already price in years of growth. The supply chain companies, by contrast, are mostly public, mostly cheap, and mostly unwatched by mainstream investors. A trader with 28 years of experience on a trading desk identified this asymmetry as the core of the investment thesis: the visible business of companies like Butterfly is already real and growing, but the optionality on top of it, driven by BCI breakthroughs, remains unpriced.

The brain-mapping revolution is not a distant science-fiction scenario. It is happening now, with measurable milestones and real capital flowing into the companies that enable it. The question for investors is not whether the technology will scale, but which companies will capture the most value as it does.